One-Year Results Reinforce Interim Findings:
mymobility Remote Care Management Platform on Apple Watch and
iPhone Yielded Similar Outcomes as Traditional Care and Resulted in
Reduced Outpatient PT and Surgery-Related ER Visits After Knee
Replacement
WARSAW, Ind., Nov. 5, 2022 /PRNewswire/ -- Zimmer Biomet
Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology
leader, today announced one-year data from a multicenter,
prospective, randomized controlled trial to evaluate the impact of
mymobility® with Apple Watch, a first-of-its-kind remote
care management platform. The data show that using mymobility with
Apple Watch following primary knee arthroplasty, commonly
known as knee replacement, can effectively guide rehabilitation,
demonstrate similar outcomes to traditional care models, and
significantly reduce the number of outpatient physical therapy (PT)
visits. In addition, use of mymobility with Apple Watch was
associated with significantly fewer surgery-related emergency
department (ED) visits, which could translate to lower costs of
care*. The data will be presented at a podium session at the 2022
annual meeting of the American Association of Hip and Knee Surgeons
(AAHKS).
![(PRNewsfoto/Zimmer Biomet Holdings, Inc.) (PRNewsfoto/Zimmer Biomet Holdings, Inc.)](https://mma.prnewswire.com/media/1603977/Zimmer_Biomet_Holdings_Logo.jpg)
"We're encouraged to find that positive early results from our
90-day analysis were sustained at the one-year follow up and
continue to reinforce that a mymobility-based remote care regimen
could yield comparable patient outcomes and potentially require
fewer healthcare resources than a traditional care model," said
David A. Crawford, MD, one of the
study's lead investigators and a joint replacement specialist at
JIS Orthopedics in New Albany,
Ohio. "With smartphone-based remote care, patients tend to
be more actively engaged in their recovery through access to
real-time data to track their progress, and with the ability to
communicate with their care teams more easily through messaging and
virtual visits. In the study, these benefits may have contributed
to lower utilization of healthcare resources, which can result in
cost savings per episode of care."
The data presented at the 2022 AAHKS annual meeting evaluated
401 patients who underwent total or partial knee arthroplasty.
Patients were randomized to a mymobility with Apple
Watch exercise and educational platform group, or a control
group who received traditional care. Among the outcomes assessed at
the one-year follow-up were Knee injury and Osteoarthritis Outcome
Score, Joint Replacement (KOOS, JR), PT visits, readmissions, and
ED/urgent care (UC) visits.
Key data findings include:
- Patients in the mymobility with Apple Watch group who did not
require adjunct PT had significantly higher KOOS, JR scores
compared to controls at one year post-operatively (89.3±11.3 vs
83.8±14.6, p=0.02).
- Significantly fewer patients in the mymobility with Apple Watch
group required post-operative physical therapy (60.6% vs. 94.6%,
p<0.001).
- Overall KOOS, JR scores were similar between control group and
mymobility with Apple Watch group at one year (83.8±14.6 vs 84.1
±14.0, p=0.88).
- The change in KOOS, JR scores from pre-operative levels were
similar at one year for the control group and the mymobility with
Apple Watch group (32.1±17.4 vs 31.5±17.1 points, p=0.51).
- Significantly fewer patients in the mymobility with Apple
Watch group utilized surgery-related ED/UC care compared to
the control group (1.3% vs 5.4%, p=0.03).
- Similar rates of readmission were observed between the
mymobility with Apple Watch group and the control group (3.8% vs
2.1%, p=0.36).
"The past two years have brought into greater focus the benefits
and conveniences of remote care, which is rapidly becoming the new
normal for many people around the world," said Nitin Goyal, M.D., Chief Science, Technology and
Innovation Officer at Zimmer Biomet. "By undertaking a large
randomized controlled trial comparing outcomes associated with a
smartphone-based remote care model versus a traditional care model,
Zimmer Biomet is proud to be at the forefront of efforts to
validate platforms, like mymobility with Apple Watch, as a viable
alternative to the standard of care."
About mymobility® with Apple
Watch
mymobility with Apple Watch and iPhone acts as a
virtual care team member by providing patients with support and
guidance at the direction of their healthcare professional as they
prepare for and recover from orthopedic procedures from the comfort
of their home. For patients who have a compatible smartphone, and
who are clinically suited for remote care, mymobility leverages the
powerful sensors on Apple Watch and iPhone to measure a patient's
activity (e.g., number of steps, walking asymmetry, walking speed,
flights of stairs) and post-operative progress. mymobility with
Apple Watch also enables virtual connections between patients and
healthcare professionals throughout the surgical episode of care,
with the goal of lowering the overall cost of care. Pre- and
post-operative data collected by mymobility with Apple Watch can
also be combined with intra-operative data from patients who
undergo joint replacement with ROSA® Robotics and is
then seamlessly consolidated and analyzed to uncover new clinical
insights throughout the episode of care and to help surgeons and
care teams make informed patient care decisions. Visit
zimmerbiomet.com/mymobility to learn more about mymobility
with Apple Watch.
About Zimmer Biomet
Zimmer Biomet
is a global medical technology leader with a
comprehensive portfolio designed to maximize mobility and improve
health. We seamlessly transform the patient experience through
our innovative products and suite of integrated digital and robotic
technologies that leverage data, data analytics and artificial
intelligence.
With 90+ years of trusted leadership and proven expertise,
Zimmer Biomet is positioned to deliver the highest quality
solutions to patients and providers. Our legacy continues to
come to life today through our progressive culture of evolution and
innovation.
For more information about our product portfolio, our operations
in 25+ countries and sales in 100+ countries or about joining our
team, visit www.zimmerbiomet.com or follow Zimmer Biomet
on Twitter at www.twitter.com/zimmerbiomet.
Cautionary Statement Regarding Forward-Looking
Statements
This news release contains forward-looking
statements within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements include, but are not limited to, statements concerning
Zimmer Biomet's expectations, plans, prospects, and product and
service offerings, including new product launches and potential
clinical successes. Such statements are based upon the current
beliefs and expectations of management and are subject to
significant risks, uncertainties and changes in circumstances that
could cause actual outcomes and results to differ materially. For a
list and description of some of such risks and uncertainties, see
Zimmer Biomet's periodic reports filed with
the U.S. Securities and Exchange Commission (SEC). These
factors should not be construed as exhaustive and should be read in
conjunction with the other cautionary statements that are included
in Zimmer Biomet's filings with the SEC. Forward-looking statements
speak only as of the date they are made, and Zimmer Biomet
disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise. Readers of this news release are
cautioned not to rely on these forward-looking statements, since
there can be no assurance that these forward-looking statements
will prove to be accurate. This cautionary statement is applicable
to all forward-looking statements contained in this news
release.
*A comparative analysis of costs was not part of this
study.
Apple Watch and iPhone are registered trademarks of Apple,
Inc.
Media
|
|
Investors
|
Meredith
Weissman
|
|
Keri Mattox
|
703-346-3127
|
|
215-275-2431
|
meredith.weissman@zimmerbiomet.com
|
|
keri.mattox@zimmerbiomet.com
|
|
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-announces-one-year-data-from-mymobility-clinical-study-at-2022-aahks-annual-meeting-301669492.html
SOURCE Zimmer Biomet Holdings, Inc.